Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00435955 |
Recruitment Status : Unknown
Verified February 2007 by Azienda Ospedaliera San Giovanni Battista.
Recruitment status was: Active, not recruiting
First Posted : February 16, 2007
Last Update Posted : February 16, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Follicular Lymphoma | Procedure: High dose chemotherapy with autologous transplantation Drug: Rituximab | Phase 3 |
The place of intensified regimens with autologous stem cell transplantation (ASCT) is poorly defined in FL at diagnosis . Most data arise from studies performed in the pre-Rituximab age. According to these studies, ASCT improved overall survival versus standard salvage approaches in relapsed patients with a high proportion of patients achieving a durable molecular remission. Data at diagnosis are less clear. Three studies have been so far published with contradictory results. Two of these studies showed that intensive therapy ensures a better disease control although in one study a significant extra-mortality from secondary tumors was observed in the intensified arm. A third study found no advantage for patients treated intensively. These results led to the widespread notion that ASCT is not superior to conventional chemotherapy in unselected FL patients. Our previous non-randomized experience employing high dose sequential chemotherapy with a final TBI-free ASCT added some clues to these considerations. Our study employs an autografting procedure which is associated to fewer secondary tumors as it does not include total body irradiation. Moreover we have observed that the our regimen (named HDS) is particularly effective in high-risk patients, suggesting that this specific subgroup is the most appropriate setting for intensified regimens
The present multicenter open label randomized trial took advantage of these observations. In addition we have included Rituximab in both arms as the inclusion of this novel agent is expected to significantly modify the performance of available treatments. We have thus compared a Rituximab-supplemented version of HDS (R-HDS) regimen with six CHOP courses supplemented by an identical number of Rituximab courses. Aim of the study was verify if an intensified approach could be beneficial as first line treatment of high-risk FL patients in the Rituximab age.
Study Type : | Interventional (Clinical Trial) |
Enrollment : | 240 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | MULTICENTER RANDOMIZED PROGRAM COMPARING HIGH-DOSE CHEMOTHERAPY + RITUXIMAB AND PERIPHERAL BLOOD PROGENITOR CELL (PBPC) AUTOGRAFT vs. CHOP + RITUXIMAB AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA |
Study Start Date : | March 2000 |

- Event free survival at three years
- Overall survival
- CR rate
- Progression free survival
- Disease free survival I
- Incidence of secondary myelodisplasia and solid cancer
- Rate of molecular remission
- Predictive value of molecular remission

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Follicular Lymphoma at diagnosis
- Stage >I
- age-adjusted I.P.I. score 2 or 3 or three or more adverse factors of the I.L.I. score
Exclusion Criteria:
- Serum positivity for HIV, HCV. HBsAg-positive only if active viral replication, assessed by HBV-DNA was present.
- Major alterations of heart, lung, kidneys, liver, except for those directly disease-related;
- Evidence of second tumors;
- Previous chemotherapy( except patients who received limited radiotherapy);
- Cerebral or CNS involvement.
- Drug addiction or severe psychiatric disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00435955
Italy | |
Divisione di Ematologia Universitaria | |
Torino, Italy, 10154 |
Principal Investigator: | Corrado Tarella, MD | Università di Torino, Azienda Ospedaliera San Giovanni Battista | |
Principal Investigator: | Marco Ladetto, MD | Università di Torino Azienda Ospedaliera San Giovanni Battista | |
Principal Investigator: | Alessandro Pileri, MD | Università di Torino Azienda Ospedaliera San Giovanni Battista (Now retired) | |
Principal Investigator: | Mario Boccadoro | Università di Torino/Azienda Ospedaliera San Giovanni Battista B | |
Principal Investigator: | Alessandro Gianni | Istituto Tumori di Milano, Milano Italy |
ClinicalTrials.gov Identifier: | NCT00435955 |
Other Study ID Numbers: |
3320 |
First Posted: | February 16, 2007 Key Record Dates |
Last Update Posted: | February 16, 2007 |
Last Verified: | February 2007 |
Follicular lymphoma age adjusted IPI >1 IIL score > 2 |
Molecular remission High dose chemotherapy and autologous transplantation Rituximab |
Lymphoma Lymphoma, Follicular Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
Lymphoma, Non-Hodgkin Rituximab Antineoplastic Agents, Immunological Antineoplastic Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |